Mithra’s new CEO has immediately signaled a potential sale for the firm’s generics business as it looks to focus on branded assets in women’s health. Meanwhile, Sawai has reorganized its management team, the longtime chair of Viatris is moving on to another role, and a former AAM vice-president has joined Sandoz.

Kinnate presented early monotherapy and combination data for its pan-RAF inhibitor at AACR, but its prioritization of BRAF Class II drew analyst concerns that its focus might be too narrow.

Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.

As Japan faces skyrocketing syphilis cases, hopes have been high among domestic physicians for a single-dose therapeutic in the form of benzylpenicillin injection. But the country has approved the drug only recently and in answer to a push from doctors on the front line.